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Background: DSM-5 introduced the diagnostic category of
substance/medication-induced bipolar and related disorder. This systematic review
examines published reports linking mania with the consumption of herbal medicines
(HM), excluding cannabis. Putative pathophysiological mechanisms that may account
for the reported HM being associated with mania are discussed.
Methods: A systematic search of EMBASE, CINAHL, Health Source, PsychINFO, and
PubMed. The quality of case reports meeting inclusion criteria was assessed using the
modified Quality Assessment Scale by Agbabiaka.
Results: Nineteen single and seven multiple-case reports met inclusion criteria. These
yielded a study sample of 35 case reports, 28 of herbal medicine associated mania, 5 of
hypomania, and twomixed states, in 17 females [age in years M(SD)= 43.1(13.2)] and 18
males [40.7(18.1)]. A total of 11 herbal medicines were implicated. Case reports by herbal
medicine (number of reports) comprised: St John’s wort (Hypericum perforatum) (14);
Ginseng (Panax ginseng) (5); brindleberry (Garcinia cambogia) (4); ma-huang (Ephedra
sinica) (3); “herbal slimming pills” (2); Herbalife products (2); Hydroxycut (1); horny
goat weed (Epimedium grandiflorum) (1); “herbal body tonic” (1); celery root (Apium
graveolans) (1), and a “herbal mixture” (1). All case reports were associated with use
rather than withdrawal of herbal medicines. Only one case report was rated for probability
of association using a standardized algorithm. Laboratory assays to confirm composition
of the herbal preparation were reported in only one article describing two cases and
indicating admixture of a likely causal pharmaceutical in the herbal preparation.
Conclusions: Causal attributions are problematic given the limited number of reports,
antidepressant co-prescribing in 7 cases, insufficient data regarding pattern and type
of herbal medicine use, and lack of a reference frequency for spontaneous mania.The
quality assessment scores across the 26 papers (35 case reports) were as follows:
low quality (0), lower-medium quality (9), upper-medium quality (10) and high quality
(7). Putative pathophysiological mechanisms were postulated for nine of the 11 herbal
medicines and centered on HPA-axis activation and increased monoamine activity.
Bostock et al. Mania Associated With Herbal Medicines
Systematic study of the association between herbal medicines and the course of bipolar
disorder may contribute to defining targets for pathophysiological research.
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INTRODUCTION
DSM-5 introduced the diagnostic category of
“substance/medication-induced bipolar and related disorder.”
This diagnosis requires a temporal association between
occurrence of mania and the use or withdrawal of substances or
medications. The precipitating agents may include intoxicating
drugs such as cannabis or amphetamines, prescribedmedications
for mood disorders such as antidepressants, prescribed
medications for other illnesses such as steroids, and herbal
medicines (HM). DSM-5 sets a less restrictive standard for the
diagnosis of substance/medication-induced bipolar and related
disorder than for mania. Criterion A for mania, as required
for a diagnosis of bipolar disorder, is “A distinct period of
abnormally and persistently elevated, expansive, or irritable
mood and abnormally and persistently increased activity or
energy, lasting at least 1 week and present most of the day,
nearly every day (or any duration if hospitalization is necessary)”
(1). This compares with criterion A for substance/medication-
induced bipolar and related disorder “a prominent and persistant
disturbance in mood that predominates in the clinical picture
and is characterized by elevated, expansive or irritable mood.”
The concept of substance/medication-induced mania
antedates the DSM-5 classification, for example it was denoted
as bipolar disorder-III in Akiskal’s classification of bipolar
spectrum disorders (2). Mania associated with the antidepressant
medication imipramine was reported by Ball and Kiloh (3) and
mania has also been associated with lithium withdrawal (4).
The first reported association of mania with a HM was in 1984
by Price et al. who explored the relation of yohimbine, an α-2
adrenergic receptor antagonist, to mania under experimental
conditions (5). A number of substances have beneficial effects
in bipolar disorder and are prescribed medications in routine
treatment of mania for example lithium, sodium valproate and
atypical antipsychotics, and in bipolar depression for example
lithium, lamotrigine, atypical antipsychotics and selective
serotonin reuptake inhibitors (6). Their precise mechanism of
action is not fully understood, reflecting a lack of understanding
of the pathophysiology of mania and depression. The study
of substance/medication-induced bipolar and related disorder,
notwithstanding limitations of causal attributions, may further
our understanding of brain mechanisms relevant to the
occurrence and course of bipolar disorder. This is particularly so
for mania which has a strikingly unique set of clinical features, is
often of abrupt onset and has a relatively short duration with a
median of 13 weeks (7).
Many conventional drugs originate from plant sources (8).
HM or phytotherapy refers to the use of plant-based medicinal
preparations, a subset of complementary and alternative
medicines (CAM). In the United States, HM are regulated
as food products and therefore are not subject to the phases
of clinical testing that pharmaceuticals must undergo prior to
market release. Manufacturing standards are in keeping with
those applicable to other foods (9), the strength and composition
of HMmay therefore vary widely.
According to survey data, the use of CAM is prevalent and
increasing throughout many Western countries (10–12). CAM
usage is common in persons with psychiatric illness. In a survey
of CAMusage among psychiatric inpatients (n= 82) it was found
that 63% used at least one CAM modality within the previous
12 months, including 44% who used HM (13). This may be
attributed in part to factors such as side effects of conventional
medicines, ready access without prescription, a belief that HM
cause no harm, and in the case of bipolar illness, traits such as
novelty seeking in mania or hypomania (14, 15). In a survey
of 826 new patients presenting at a CAM clinic, 578 (70%)
had a mental disorder and reported lower quality of life and
greater levels of stress than those without a mental disorder.
Among patients with a mental disorder, the major reasons for
choosing complementary therapies were personal preference,
interest, or beliefs in complementary therapies (44.3%) including
as a treatment of last resort (30.7%) (16).
In a cross-sectional survey of 100 older (>55 years) inpatients
and outpatients with bipolar disorder (n = 50) or major
depression (n= 50), the use of herbal and nutritional compounds
(HNC) was examined to determine several factors including,
knowledge of products, perceived efficacy and safety, patterns
of use and discussion of use with health care providers.
Approximately 30% of respondents reported using oral HNC,
40% thought that they were Food and Drug Administration
regulated and 14–20% preferred to take HNC to psychotropic
medications (17).
A review of CAM therapies in the treatment of bipolar
disorder, noted that few rigorous clinical studies have been
conducted in this patient population (14). The herbal preparation
Free and EasyWanderer Plus has been examined as an adjunct to
carbamazepine (CBZ) in a double-blinded, randomized placebo-
controlled trial in patients with bipolar disorder in manic and
depressive phases (18). When compared to CBZ monotherapy,
at week 4 and 8 of the trial, the HM combined with CBZ
resulted in significant improvement in depression but not
mania.
Although cannabis has largely been seen as an illicit drug, it
is now entering into conventional medicine under the rubric of
“medicinal cannabis.” Cannabis has been extensively researched
in relation to its acute and chronic effects in psychosis. Discussion
of the role of cannabis in bipolar disorder is beyond the
scope of this article but is summarized in a systematic review
and meta-analysis by Gibbs et al. (19). This reported that, on
balance, in pre-existing bipolar disorder, cannabis may worsen
the occurrence of manic symptoms and may also act as a causal
risk factor in the incidence of manic symptoms.
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This paper presents a systematic review of single andmultiple-
case reports of mania associated with herbal medicines other
than cannabis. A more comprehensive understanding of what
precipitates mania in vulnerable individuals may potentially lead
to new understandings of the illness and the substrates that are
implicated in bipolar disorders.
METHOD
This review of reports of herbal medicine-associated mania was
conducted in accordance with the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA) guidelines
(20).
Inclusion Criteria: (a) published between 1980–2017 (b) in a
peer-reviewed journal (c) included adult participants (> 18 years)
(d) published in the English language. Exclusion criteria: (a)
psychosis in the absence of manic features (b) secondary manias
due to infection, neoplasm, epilepsy, and metabolic disturbances
(c) systematic reviews (d) relating to cannabis.
Identification of Studies
In the first week of September 2017, a search of the electronic
databases EMBASE, CINAHL, Health Source, PsychINFO and
PubMed was conducted to find published associations between
HM and mania. The search was commenced by identifying in
each database the controlled vocabulary terms/ subject terms
related to herbal medicines (group 1) and bipolar disorder
(group 2). All subject terms were exploded. Subject terms in the
respective databases for group 1 were herbal medicine (PubMed);
herbal medicine and medicinal herbs and plants (EMBASE and
PsychInfo); medicine and herbal medicine (CINAHL and Health
Source). Additionally, 182 free text terms that related to herbal
medicines, including botanical names, (see Appendix 1) were
combined with “OR.” Subject terms for group 2 were bipolar
disorder, cyclothymic disorder (PubMed); bipolar disorder,
cyclothymia (EMBASE and PsychInfo); and bipolar disorder
(CINAHL and Health Source). The free text terms bipolar
disorder, mania, cyclothymia, manic-depressive psychosis, manic
state, bipolar depression and manic disorder were searched for
and combined with “OR.” Finally, group 1 and group 2 were
combined with “AND.”
A purpose-built coding sheet was used to assess articles against
the inclusion criteria. To assess accuracy of initial screening KK
and EB separately rated 20 titles and abstracts, randomly selected
from the records screened using the RANDBETWEEN function
in Microsoft Excel version 15.23.2. Inter-rater agreement on
exclusion/inclusion was 100%.
Quality Assessment of Case Reports
Authors EB and KK individually assessed all included case
reports for quality, according to the following nine criteria:
classification on Quality Assessment Scale by Agbabiaka; use of
a validated instrument to assess for causality (Naranjo or WHO-
UMC score); botanical name of herbal medicine stated; herbal
material assessed for authentication; herbal material assessed for
adulteration; characteristics of herbal medicine detailed (e.g.,
plant part, extract type); product brand name and manufacturer
detailed; batch numbers; herbal dosage specified. The case report
Quality Assessment Scale by Agbabiaka (21) as modified by
Hung, Hillier and Ernst (22) has 21 questions rated as “yes,”
“unclear,” and “no,” each item scored between 0 and 2 points for
a total score out of 42 points. Each case report was classified as:
low quality (0-14 points), lower medium quality (15–21 points),
upper medium quality (22–28 points) or high quality (29–42
points) as recommended by Agbabiaka (21).
After each paper had been assessed EB and KK discussed
the results and came to a consensus score. Inter-rater reliability
on the Quality Assessment Scale by Agbabiaka was calculated
using several indices: raw agreement (number of agreements
for individual items divided by number of possible agreements),
kappa coefficient and intraclass correlation coefficient (ICC).
Raw agreement ranged from 52.4 to 95.2% for individual articles
with mean raw agreement 75.6% (95% CI [71.2%, 80.1%]).
Separate kappa coefficients were calculated between the two
raters for all items on each of the 26 articles. To obtain mean
kappa, the 26 kappa coefficients were first transformed using
Fisher’s transformation to achieve linearity. The mean and 95%
CIs were calculated, then back-transformed to original kappa
units. Individual kappa coefficients ranged from 0.16 to 0.92.
Mean kappa was 0.60 (95% CI [0.50, 0.68]). Applying the criteria
of Landis and Koch this represents a moderate-to-substantial
level of agreement (23). The ICC between the two raters was
calculated from the total score for each article using two-way
ANOVA (24). Each item on the scale was rated as 0, 1, or 2. With
21 items the maximum possible score for an article was 42. Rater
and article were treated as separate, random effects in the model.
For total scores the means were 24.5 (SD = 6.2) for EB and 24.7
(SD = 5.6) for KK. The inter-article correlation between raters
was 0.70 (95% CI [0.42, 0.85]). The ICC was 0.82 (95% CI [0.60,
0.92]) indicating a good-to-excellent level of agreement (25).
RESULTS
The results of the search strategy are summarized in the PRISMA
diagram (Figure 1). There were no randomized clinical trials
of HM in mania. The study sample comprised 35 case reports,
from 19 single and 7 multiple-case reports, of an association
between mania and use of HM. Details of each case report are
summarized in Table S1, including clinical and demographic
details, the composition of the HM, other medications, and
treatment outcomes.
In summary, the reports included 17 females [age in years
M(SD) = 43.1(13.2)] and 18 males [40.7(18.1)]. Case reports,
grouped by HM (number of reports) comprised: St John’s
wort (Hypericum perforatum) (14); Ginseng (Panax ginseng)
(5); brindleberry (Garcinia cambogia) (4); ma-huang (Ephedra
sinica) (3); “herbal slimming pills” (2); Herbalife products (2);
Hydroxycut (1); horny goat weed (Epimedium grandiflorum)
(1); “herbal body tonic” (1); celery root (Apium graveolans)
(1), and “herbal mixture” (1). Fourteen cases were taking
concurrent prescription medications, comprising antidepressant
(SSRI 3; SNRI 2; tricyclic 1; NDRI 1); lithium (1); antipsychotic
(2); atypical antipsychotic (1); anti-epileptic (2); statin (2);
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FIGURE 1 | Preferred reporting items for systematic reviews and meta-analysis flow diagram of included studies.
beta-blocker (1); NSAID (2); sildenafil (1) and a synthetic
glucocorticoid (1). A psychiatric history was noted in 24 of the
35 cases of HM-associated mania, diagnoses included depression
(n = 11) bipolar disorder type I (BDI) (n = 5), bipolar disorder
type II (BDII) (n = 2), post-traumatic symptoms (n = 1),
eating disorder (n = 2), past suicide attempt (n = 1) and
substance/medication-induced bipolar and related disorder (n=
1). For the whole sample the time to onset of manic symptoms
from commencing the HM was between 2 days and 2 years with
a median of 4 weeks.
St John’s Wort (Hypericum perforatum)
Fourteen case reports described mania, hypomania and two
mixed states associated with St John’s wort, in seven females [age
in years M(SD)=49.4(12.4)] and seven males [39.4 (17.8)]. Stated
reasons for taking St John’s wort were depression (12) (26–34),
to improve energy (1) (29) and to relieve symptoms of post-
traumatic stress (1) (29). The time of onset of manic symptoms
from commencing HM ranged from 3 days to 2 months. The
mental status on examination was consistent with mania and two
mixed state in the 14 cases. Three cases had a past psychiatric
history of bipolar disorder, and eight of unipolar depression of
whom four were concurrently taking antidepressants. In eight
cases, the dose of the St John’s wort preparation was not specified.
Ginseng (Panax ginseng)
There were five case reports of Ginseng-associated mania in
our study sample, two females [46(10) years] and three males
[42.7(25.7)]. Stated reasons for taking Ginseng were to boost
energy (2) (35, 36), fatigue (1) (37), erectile dysfunction (1) (34)
and one unknown (1) (38). The time to onset of symptoms
between taking Ginseng and mania ranged between 10 days and
2 months prior. Of these five cases, two had a prior history
of depression, one of substance-induced hypomania, two had
no past psychiatric history. The reported range of daily doses
of Ginseng in the case reports were 500–750mg of root or
300mg−20 g of extract, compared to a recommended short-term
dose range of 0.5–2 g of dry Ginseng root, equivalent to 200–
600mg of extract, and long-term dose of 1 g of dry root (39). In
two cases, the recommended long-term dose was far exceeded.
Brindleberry (Garcinia cambogia)
There were two case reports of mania and one each of
manic psychosis and hypomania, involving Garcinia cambogia,
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2 females [42.5(8.5) years] and 2 males [37.5(12.5)]. The stated
reason for taking the HM was weight loss (40, 41) and three
patients had a past history of bipolar disorder. In each case, the
dose of Garcinia cambogia was not specified. The time to onset
of manic symptoms from commencing the HM ranged from 2–6
weeks. Two cases were concurrently taking antidepressants and
mood stabilizers.
Ma-Huang (Ephedra sinica)
In three cases, ma-huang (in one case along with chromium
picolinate and caffeine) was associated with manic-like
symptoms in individuals without a history of bipolar illness, two
females [30.5(9.5) years] and one male [45 years]. Stated reasons
for taking the HM were weight loss (42, 43) and heightened
alertness and to prevent drowsiness (44). Past psychiatric history
included hospitalization for alcohol poisoning, and bulimia
without purging with a description of manic-like symptoms. The
family psychiatric history included possible bipolar disorder and
schizophrenia. The time to onset of manic symptoms ranged
between 5 days and 2 months. In each case the dose of the HM
was unknown, concurrent medication in one case comprised
thyroid hormone and recently discontinued antidepressant.
Herbalife Products
Two cases reported mania associated with the use of a Herbalife
product for the stated reason of weight loss (45, 46). Both were
male [32.5 (6.5)] and neither had a personal or family history
of bipolar disorder or were taking prescribed medication. In
one case, the patient became manic after taking “large amounts”
of the products both as tablets and tea. The time to onset of
manic symptoms ranged between 2 and 20 days. In a subsequent
published letter regarding the above case reports, by authors
affiliated with the Herbalife brand, (47), it was noted that the
case reports did not specify the precise product (as opposed to
the brand) and/or ingredients taken in these two cases.
Herbal Slimming Pills
In a multiple-case report by Chong, two cases of manic-like
psychosis were associated with the use of “Herbal slimming pills”
(48). An assay of the HM identified that it contained the anti-
depressant pharmaceutical sibutramine. The authors attributed
the occurrence of mania to this adulterant.
There were five single case reports that related an HM
(ingredients see Table S1) to mania, involving Hydroxycut (49),
Horny goat weed (Epimedium grandiflorum) (50), “herbal body
tonic,” prescribed for anger (51), celery root (Apium graveolans)
formenopausal symptoms (52) and a “herbal mixture” prescribed
for fatigue (53).
QUALITY ASSESSMENT OF CASE
REPORTS
In addition to the systematic review of HM associated mania, we
also assessed the quality of the individual case reports. The results
are shown in Table S2.
Applying Hung, Hillier and Ernst’s (22) modified version of
the Agbabiaka tool (54), the distribution of the quality assessment
scores across the 26 papers, covering 35 case reports, was
as follows: low quality (0), lower-medium quality (9), upper-
medium quality (10) and high quality (7). Only one single case
report used a validated instrument to assess causality, the Naranjo
scale. The botanical name was listed in 19 cases in 18 papers.
Only 1 paper presenting 2 case reports used a laboratory assay
to confirm the composition of the HM. The composition of the
HM, for example plant part used and extract type, was detailed in
only 1 case report. The brand name andmanufacturer were stated
in 3 case reports. The dosage of the HM was specified in only 18
of the case reports. Of the study sample, 2 case reports of 1 HM
were assessed for adulteration. The batch number was provided
in none of the case reports. Herbal dosage was detailed fully in 6
and partially in 3 cases.
DISCUSSION
This review examined case report evidence regarding
HM-associated mania. Those included were: St John’s
wort (Hypericum perforatum); Ginseng (Panax Ginseng);
Brindleberry (Garcinia cambogia); ma-huang (Ephedra sinica);
“herbal slimming pills”; Herbalife products; Hydroxycut;
horny goat weed (Epimedium grandiflorum); “herbal
body tonic”; celery root (Apium graveolans), and “herbal
mixture.” Where possible the candidate pathophysiological
mechanisms are discussed in turn, as are other factors
which may have contributed to the onset of mania in the
individuals included in the study. There is an inherent
difficulty in making attributions regarding the causality
of HM on mania as the course of bipolar disorder is
unpredictable.
Of the 35 case reports included in this review, 5 were isolated
reports of one HM and two cases (both “herbal slimming pills”)
were attributed to a contaminant. The remaining 28 cases were
accounted for by five HM, all of which were the subject of two
or more case reports of mania. Over a publication period of 38
years (1980–2017) this is a small yield of reported concurrence
of HM usage and mania. The small numbers and unreliability of
discerning and reporting a link between mania and HM preclude
any definitive statement as to whether any association is causal or
coincidental.
With respect to St John’s wort, there is a high specificity of
the stated reason for taking the HM to be for treatment of
depression (11 of 14 St John’s wort cases compared to 0 of 21
other HM). There was also greater morbidity in the psychiatric
history of the St John’s wort cases (13 of 14 cases compared
to 11 of 21 for other HM), in the family history of mood
disorder (6 of 14 compared to 2 of 21) and concurrent
antidepressant prescribing was more common (4 of 14 compared
to 4 of 21). Competing explanations for these patterns include
an increased diathesis toward bipolar disorder, fluctuations of
established affective illness, antidepressant-associated mania and
HM-associated mania. These factors are not mutually exclusive,
for instance according to Craddock and Sklar, a family history
of bipolar disorder is an important clinical predictor of a likely
bipolar course in a patient who presents with one or more
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episodes of depression even before their first personal episode of
mood elevation (55).
The mechanism by which St John’s wort may alter
susceptibility to mania is not well understood. As with
antidepressants, it is difficult to distinguish spontaneous episodes
of mania from St John’s wort-associated switching (56). Angst
et al. analyzed the time course and risk factors for a diagnostic
change from major depression to bipolar disorders over an
average of 20 years from onset. Diagnostic change from
depression to bipolar type I occurred in approximately 1% and
bipolar type II 0.5% of patients per year (57). In patients with
major depressive disorder treated with antidepressants, it has
been found that antidepressant-associated mania or hypomania
occurs at an average frequency of 3.42% of cases per year, but it is
unclear to what extent switching represents undiagnosed bipolar
disorder or a direct pharmacological effect of antidepressants
(58).
Depression is one of the most commonly cited reasons
for using CAM (59). The prevalence of depression in the
United States has been reported to have increased between
2005 and 2015 (60). For many patients with depression, HM
which are in many countries, predominantly available over-
the-counter, may be an attractive alternative to conventional
medicines. There is a substantial evidence base from randomized
controlled trials supporting the use of St John’s wort in mild-to-
moderate depression. In a systematic review and meta-analysis
comprising 23 randomized trials of St John’s wort in outpatients
with mild-to-moderate depression (N = 1757), it was found that
Hypericum perforatum extracts were significantly more effective
than placebo (61).
St John’s wort has a variety of actions that may contribute
to its therapeutic effects. In vitro, it acts on neurotransmitter
regulation, including beta adrenergic and glutamate receptors,
and ion channel conductance. Hypericin (an active constituent
of St John’s wort) inhibits serotonin reuptake, and 5-HT1A
and 5-HT1B receptor changes are associated with prolonged
use (62). According to Fahmi et al, in animals, hypericum
is effective in three major biochemical systems relevant for
antidepressant activity including inhibition of synaptic reuptake
of serotonin, noradrenaline and dopamine (26). In the human
case reported by Barbenel of concurrent prescribing of St John’s
wort and sertraline in a patient following surgery for crypto-
orchidism, alteration of testosterone and gonadotrophin levels
and interactions of antidepressant and St John’s wort were further
considerations.
With five case reports of Ginseng associated mania it was
the second most commonly reported HM after St John’s wort.
Based on the belief that it is a panacea and promotes longevity,
Ginseng root has been used for over 2000 years (63). There
are a number of plants that share the common name Ginseng
however only three of these are from the genus Panax (Panax
ginseng, P. notoginseng and P. quinquefolius). Other “ginsengs”
include Siberian (Eleutherococcus senticosus), Indian (Withania
somnifera), and Brazilian (Pfaffia paniculata) (64, 65). The most
important constituents of Panax ginseng are the ginsenosides, of
which 15 different types have been identified (35).
In a systematic review of RCTs examining the efficacy of
Panax ginseng root extracts for a number of indications, it
was concluded that there is contradictory evidence that Ginseng
improves physical performance and immunological measures. It
may have beneficial effects on psychomotor performance and
cognitive behavior. No trial has confirmed the alleged age-
delaying properties of Ginseng. Results suggesting a reduction of
blood glucose levels in type-II diabetic patients require further
investigation (64, 65). With Panax ginseng, two mechanisms
of action in depression have been advocated, firstly, an
activating effect of ginsenosides on the HPA-axis resulting in
elevated corticotropin and corticosteroid levels (33). Secondly,
monoamine signaling could also be affected by ginsenosides
(66, 67).
Thirteen of 35 case reports in our study sample involved
adverse psychiatric effects of weight loss products including
brindleberry (Garcinia cambogia), ma-huang (Ephedra sinica),
“herbal slimming pills,” Herbalife products and Hydroxycut.
The social stigma of obesity, a desire to lose weight without
making drastic lifestyle changes, and frustration at previous
failed attempts are commonly reported reasons for using dietary
supplements which are readily available and advertised as being
“natural” and safe (68).
In one 12-week randomized placebo-controlled trial,Garcinia
cambogia failed to produce significant weight loss and fat loss
beyond that observed with a placebo (69). In contrast, another
double-blind placebo RCT found thatGarcinia cambogia reduced
abdominal fat accumulation in participants (70). Other human
research has confirmed the potential of Garcinia cambogia/HCA
in stimulating fat oxidation, increasing serotonin release in
brain cortex and normalizing lipid profiles (71). The main
active ingredient of Garcinia cambogia is hydrocitric acid which
has serotonergic effects and has been implicated in serotonin
syndrome (38). Hydrocitric acid is the putative mediator of this
HM weight loss effect; it is thought to promote the release and
synaptic availability of serotonin thus influencing appetite (41).
The effects of Hydroxycut were attributed to the inclusion of
Garcinia cambogia in the preparation (49).
Partin and Pushkin, who reported a case of hypomania
associated with horny goat weed (Epimedium grandiflorum)
proposed that this may have been due to the addition of other
unidentified herbs and pharmaceuticals (50). However, these
were not explicitly tested for.
Ma-huang (Ephedra sinica) is native to China and Mongolia
and contains sympathomimetic compounds known as Ephedra
alkaloids. Traditionally used to treat asthma and hay fever
symptoms, more recently it has been combined with caffeine or
botanical sources of caffeine (for example Guarana) for weight
loss purposes (68). In a 6–month RCT of herbal Ephedra/
caffeine for weight loss, it was found that 90/192 mg/day of
herbal ephedra/caffeine promoted weight and body fat reduction
(72). In another randomized double-blind trial of a herbal
supplement containing ma-huang-guarana for weight loss, it was
found that the active treatment produced significant effects (73).
Ma-huang contains variable amounts of ephedrine congeners
which enhance norepinephrine release in central noradrenergic
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neurons. Ephedrine also has direct agonist activity at alpha and
beta-adrenergic receptors (44).
Sibutramine is an appetite-suppressing agent that is a
norepinephrine and serotonin reuptake inhibitor, initially
developed as an antidepressant (48) its use has been associated
with mania (74, 75) and hypomania (76). In a recent
analytical study of 447 weight loss products, 119 were found
to be adulterated with one or more weight loss compounds
including sibutramine, its metabolites benzyl sibutramine and
desmethyl sibutramine; phenolphthalein; bisacodyl; furosemide;
liothyronine (T3); and thyroxine (T4) (77). This demonstrates
the importance of having regulatory bodies oversee CAM
manufacturing practices and to regularly assess certain classes of
CAM products for adulterants (such as weight loss products).
These incidences of mania associated with HM weight-loss
products highlight the fact that they may be considered safe and
harmless by consumers when they have the propensity to trigger
adverse events in vulnerable individuals (78).
Khalid et al. reported a case of mania associated with celery
root (Apium graveolans), St John’s wort (Hypericum Perforatum)
and venlafaxine. Mania ensued shortly after the ingestion of
celery root, which belongs to a group of plants classified as
the umbelliferous family, which contain phytoestrogens that are
structurally similar to estrogen. In this case the patient developed
elevated serum venlafaxine levels after taking celery root for
menopausal symptoms, suggesting pharmacokinetic potentiation
of the venlafaxine level by the celery root as a likely mechanism
of induction of mania (52).
Thirteen of the patients were concurrently taking
conventional medicines (as shown in Table S1) as well as
HM which may have led to herb-drug interactions resulting
in mania. This might result from alterations of absorption,
distribution, metabolism or elimination of a conventional
drug by a herbal product, that is pharmacokinetic effects (79).
Alternatively, there may be synergistic effects of a HM and
a conventional medicine reflecting common mechanisms of
action such as neurotransmitter regulation. Drug dosage is
one important factor in such herb-drug interactions as well
as in interactions with underlying biological diatheses (80). In
approximately one third of the cases reviewed the dosage of
the HM was unknown. This limits the ability to make causal
inferences regarding the dose of the HM associated with a manic
switch in vulnerable individuals.
For the whole sample the time to onset of manic symptoms
from commencing the HM (treatment-emergence interval)
ranged between 2 days and 2 years with a median of 4 weeks.
None of the HM reported associated withmania diverged notably
from this median time to onset of manic symptoms. A treatment-
emergence interval of 8–12 weeks is deemed to implicate
causality; however, a much shorter interval may be necessary
to definitively link cause and effect (81). The manic episodes
reported in the cases were mostly treated with conventional anti-
manic agents, only two reports indicate the outcome of cessation
of the HM alone on the course of mania, one indicating remission
in 2 days, the other no improvement following a switch into
depression. Thus, no general statement can be made with respect
to mania resolution on ceasing the implicated HM.
In addition to the systematic review of HM-associated mania,
we also assessed the quality of reporting (Table S2) on the
modified Quality Assessment Scale by Agbabiaka, in each of
the 26 published case report papers. The case report quality
assessment score ratings were low quality (0), lower-medium
quality (9), upper-medium quality (10) and high quality (7).
There are two algorithm-based rating instruments to assign
the probability that an adverse event (in this case mania or
hypomania) is related to a given exogenous substance, the
Naranjo and the WHO-UMC. Of the cases reviewed only one
used the Naranjo scale, none used the WHO-UMC. One study
compared the two rating scales and found that the WHO-UMC
method was more simple and less time consuming compared to
the Naranjo probability scale (82). On the 7 additional quality
criteria, the quality of reporting was satisfactory only for the
inclusion of botanical name of HM (26 of 35 cases) and to a
lesser extent HM dosage (18 of 35 cases). On the remaining
5 criteria less than 10% of papers were compliant. It is noted
that many of the reports were published before the advent of
defined quality criteria ratings, for example 19 of the 26 papers
preceded the publication of the modified Quality Assessment
Scale by Agbabiaka in 2008. Future published case reports of
adverse events should adhere to such criteria in order to improve
their overall quality and inferences which may be made from
these articles.
The current review of case reports is subject to a number of
limitations. Substance/medication-induced bipolar and related
disorder may reflect a switch in a previously unexpressed bipolar
diathesis. It is possible that the reports in the scientific literature
are subject to a confirmation bias in that clinicians are looking
for links between mania and recent use of HM. There is also a
possible effect of researcher/ publication bias, which has led to
the publication of the included studies. Ethically, it is difficult
to replicate studies which suggest a potentially harmful effect of
various HM.
The compilation of case histories presents a different sample
to that commonly seen in a randomized controlled trial setting
where fixed inclusion and exclusion criteria apply. This sample
of putative HM induced mania includes a number of patients
(n = 7) with a stated past history of a diagnosis of BD and a
further 7 patients without a BD diagnosis taking antidepressants.
This increases the likelihood that the observedmanic episode was
attributable to extant bipolar disorder or antidepressant induced
switching rather than the HM per se, although interactions of
these variables cannot be excluded.
Despite these limitations, however, there are a number of
strengths associated with the inclusion of case reports including
that the patients, episodes ofmania, time course of symptoms and
aetiological factors are described in detail, as reflected in Table
S1. The authors are generally circumspect in their judgements
regarding causality, documenting an observed association,
summarizing knowledge regarding possible mechanisms of
action, and allowing for the multiplicity of explanations that
attend a disorder of unclear etiology and pathogenesis and with a
typically fluctuating course.
Concepts of exogenous and endogenous causation of
psychoses have been debated over the past century. In 1910,
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Bonhoeffer proposed that the brain only manifested a few
stereotyped mental reactions, whether from exogenous or
endogenous origins. He recognized delirium in particular as a
presentation that could follow diverse exogenous causes. The
typical features in delerium of clouding of consciousness and
disorientation form the rationale for categorizing it separately to
the psychoses (83). Similarly, in the concept of unitary psychosis,
as elaborated by Conrad in 1959, there is no fixed relationship
between symptom picture and exogenous factors, the latter
potentially triggering a range of symptom pictures (84). Relating
these propositions to the current study on case reports of mania
associated with herbal medicines, the results are inconclusive
because it is restricted to one diagnostic category, mania, and
one class of aetiological factors, herbal medicines. Comparisons
of reports of herbal medicines associated with the onset of a
variety of mental disorders would yield information as to whether
the relationship indicates specific aetiologies of a disease (e.g.,
mania) or a broader relationship whereby a diversity of diagnostic
categories (e.g., mania, psychotic depression and schizophrenia)
are attributable to a common aetiological factor, the unitarian
view.
In summary, the reported co-occurrence of HM usage
and mania, whilst inconclusive, provides a plausible signal
as to brain mechanisms relevant to the pathogenesis of
mania. With the increasing storage of health information
in electronic health records and evolving techniques of data
mining there are prospects for the widespread application
of case report level information to the elucidation of
associations and causal links between usage of HM and the
occurrence and varied course of mental disorders including
BD.
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